Relief Therapeutics Holding SA

Company Profile

Relief Therapeutics Holding SA had its IPO on under the ticker symbol RLFTF.

The company operates in the Healthcare sector and Biotechnology industry. Relief Therapeutics Holding SA has a staff strength of 69 employees.

Stock update

Shares of Relief Therapeutics Holding SA opened at $4.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.62 - $4.05, and closed at $3.91.

This is a +0.26% increase from the previous day's closing price.

A total volume of 1,973 shares were traded at the close of the day’s session.

In the last one week, shares of Relief Therapeutics Holding SA have increased by +24.92%.

Relief Therapeutics Holding SA's Key Ratios

Relief Therapeutics Holding SA has a market cap of $43.70 million, indicating a price to book ratio of 0.705 and a price to sales ratio of 22.1607.

In the last 12-months Relief Therapeutics Holding SA’s revenue was $6.08 million with a gross profit of $4.83 million and an EBITDA of $-31740000. The EBITDA ratio measures Relief Therapeutics Holding SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Relief Therapeutics Holding SA’s operating margin was -578.98% while its return on assets stood at -9.99% with a return of equity of -31.07%.

In Q2, Relief Therapeutics Holding SA’s quarterly earnings growth was a positive 0% while revenue growth was a negative 14.5%.

Relief Therapeutics Holding SA’s PE and PEG Ratio

Forward PE

1.3019

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-7.08 per share while it has a forward price to earnings multiple of 1.3019 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Relief Therapeutics Holding SA’s profitability.

Relief Therapeutics Holding SA stock is trading at a EV to sales ratio of 114.4682 and a EV to EBITDA ratio of -2.3271. Its price to sales ratio in the trailing 12-months stood at 22.1607.

Relief Therapeutics Holding SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$188.80 million

Total Liabilities

$10.72 million

Operating Cash Flow

$-2382000.00

Capital Expenditure

$12500

Dividend Payout Ratio

0%

Relief Therapeutics Holding SA ended 2024 with $188.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $188.80 million while shareholder equity stood at $145.42 million.

Relief Therapeutics Holding SA ended 2024 with $0 in deferred long-term liabilities, $10.72 million in other current liabilities, in common stock, $-119599000.00 in retained earnings and $7.02 million in goodwill. Its cash balance stood at $19.24 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $16000.00.

Relief Therapeutics Holding SA’s total current assets stands at $22.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.32 million compared to accounts payable of $1.63 million and inventory worth $227000.00.

In 2024, Relief Therapeutics Holding SA's operating cash flow was $-2382000.00 while its capital expenditure stood at $12500.

Comparatively, Relief Therapeutics Holding SA paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.91

52-Week High

$14.4949

52-Week Low

$2.2

Analyst Target Price

$

Relief Therapeutics Holding SA stock is currently trading at $3.91 per share. It touched a 52-week high of $14.4949 and a 52-week low of $14.4949. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $3 and 200-day moving average was $7.59 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 368.9% of the company’s stock are held by insiders while 3895.6% are held by institutions.